The Allstate Corporation (ALL)

The Allstate Corporation is trading near the upper part of its 52-week range after a run of earnings beats, and its valuation sits far below the sector. The stock closed at $262.18, up 0.41% in the last session, and sits 6.73% below its 52-week high of $281.11 while 37.17% above its 52-week low. The reported figures show a trailing P/E of 5.92 against a sector median of 16.5, and eight straight quarterly EPS beats. Analysts are more cautious: the consensus is Hold, and the median 12-month target of $275.00 sits 4.9% above the price. Earnings from the November 4, 2026 report beat the estimate by 40.23%, yet the shares slipped 0.87% in the next session, a reminder that a beat does not automatically lift the price.

The Allstate Corporation reported EPS of $9.76 on an adjusted basis for the quarter reported on November 4, 2026, against an analyst estimate of $6.96, a beat of 40.23%. Revenue grew 10.82% in the latest quarter against the same quarter a year earlier, slightly slower than the sector median of 11.7%. Over the last eight reports the company beat the EPS estimate every time, including beats of 48.11% in August 2026 and 47.10% in April 2026. The shares rose after three of those earnings reports and fell after three others, so the beat record has not translated into a consistent first-session move. The shares fell 0.87% in the first session after the November report.

At a trailing P/E of 5.92, ALL trades 75.8% below the sector median P/E of 16.5, and its price-to-sales ratio of 0.92 is 75.3% below the sector median of 3.8. The reported GAAP earnings per share over the last 12 months were $44.09, well above the adjusted quarterly figures, which is the main reason the trailing multiple looks so compressed. Return on equity of 38.93% is well above the sector median of 13.8%, and debt-to-equity of 0.23 indicates a conservative balance sheet. The gap between price and earnings is the central question for an investor: the market is pricing the business as if its current earnings will not last.

Of 25 analysts with a current rating, 10 rate the stock buy or strong buy, 11 hold it and 4 rate it sell or strong sell, giving a consensus of Hold. Three months ago the buy count was also 10 out of 25, so the mix has not shifted much. Recent actions were mostly reiterations: Citigroup kept its Sell rating on November 6, 2026, Wells Fargo kept its Equal-Weight rating the same day, and Barclays kept its Underweight rating on November 5, 2026. Wells Fargo upgraded the stock to Equal-Weight from Underweight on October 12, 2026. Insiders sold $132.5M of stock over the last 18 months across 28 sales with no open-market purchases, though those sales are often planned in advance or made to cover tax on vesting shares.

The base case is that ALL holds its position above its 50-day and 200-day moving averages ($245.91 and $231.03) while the market digests recent beats and a pullback in analyst enthusiasm. The stock is priced at a steep discount to peers on earnings and sales, so the pace of earnings growth is what will decide whether that discount narrows. Analysts' estimates point to EPS growth of 9.5% this fiscal year, but expected EPS shrinkage of 25.7% next fiscal year, which would weigh on the case if it holds. A move back above the 52-week high of $281.11 would need a clear improvement in the ratings mix, which currently has 10 buy ratings against 4 sell ratings out of 25. A break below the 20-day EMA near $254.95 would signal that the recent gains are fading, and the 50-day SMA of $245.91 would become the next test. The median analyst target of $275.00 and the high of $370.00 frame the upside analysts see, while the low of $191.00 marks the bearish view.

Support sits first at the 20-day EMA of $254.95, the nearest level below the price and a short-term trend line. Below it, the 50-day SMA at $245.91 is the next level a fall would meet, and it marks where the medium-term uptrend would be tested. The 200-day SMA at $231.03 is the longer-term support, and the 52-week low of $191.13 is the floor of the one-year range. On the upside, the 52-week high of $281.11 is the nearest resistance and the level a rise would meet first. The median analyst target of $275.00 sits between the price and that high and is a reference point rather than a technical level.